Drugs.com Clinical Trial ResultsOriginal article
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data for Deramiocel for Upper Limb Function in Duchenne Muscular Dystrophy
Data ReadoutpositiveDeramiocelPositive
AI Analysis
Summary
Capricor Therapeutics announced positive data from the HOPE-3 open-label extension trial of deramiocel for upper limb function in Duchenne Muscular Dystrophy. The data supports continued development of the cell-based therapeutic for this rare disease indication.
Clinical Trial Data
Phase
Extension
Primary Endpoint
Met
Outcome Details
Positive data from HOPE-3 open-label extension trial
Importance:6/10
Sentiment:
0.70
cell therapyexosome-based therapeuticsrare diseasemuscular dystrophyclinical data
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on October 5, 2026 5:10 AM